CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric†or the "Company†), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives†(the "'179 patent†), with claims to compositions and methods of treatment for novel molecules with the potential to be developed. ...